Product Name: CA19-9 Antibody
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P
Applications: Flow Cytometry: 2-4 ug/million cells in 0.1mlImmunofluorescence: 2-4 ug/mlImmunohistochemistry (FFPE): 5-10 ug/ml for 30 min at RTOptimal dilution of the CA19-9 antibody should be determined by the researcher.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Purified human protein was used as the immunogen for the CA19-9 antibody.
Host Species: Rabbit
Purification: Protein A affinity
Physical State: Liquid
CAS NO.: 1619994-68-1
Product: GSK2801
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names:
Accession NO.:
Protein Ino:
Official Symbol:
Geneid:
Background: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
PubMed ID:http://aac.asm.org/content/42/12/3245.abstract
